Techno Medica Co., Ltd.
First Quarter Financial Summary for the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)
Sales growth driven by blood collection tube preparation devices. First quarter net sales were 2.2022 billion yen, up 25.3% YoY; quarterly net income rose significantly to 1.599 billion yen. Full-year guidance has been revised; the second quarter outlook includes upward revisions, but no full-year revision. Overseas sales ratio declined to 14.6%.
Key Figures
- Sales: 2,202,353千円
- Operating profit: 236,710千円
- Net profit (quarter): 158,993千円
AI要約
Business Performance Overview
This quarter's revenue remained solid, with strong growth in blood collection tube preparation devices and systems. Domestic demand recovered, boosting sales, while overseas markets softened. Overall profitability improved markedly, with both ordinary income and quarterly net income substantially beating the prior year. The full-year outlook has been revised, reflecting the Q2 forecast adjustment, while no full-year revision is implemented.
Outlook and Key Considerations
The revised Q2 forecast anticipates that increased sales of consumables and delayed development costs will reduce selling, general and administrative expenses, with no impact on the full-year forecast. The financial position remains solid: total assets 16,239 million yen, net assets 13,709 million yen, and equity ratio 84.4%. Attention should be paid to cash, deposits, and accounts receivable movements.
Sales Trend
Operating Profit Trend
Net Profit (Quarter) Trend
Overseas Sales Ratio
Cost of Sales and SG&A Structure
Technomedica Corporation
Company overview · Stock price · Financial data · All IR
